![]() |
|
|
|
| Scientific Subdivisions | The Journal of Molecular Diagnostics | Contact AMP | Sign In | Join / Renew | Go To CHAMP 2.0 |
The AMP advocacy program endeavors to inform and influence public policy affecting molecular pathology. AMP represents its membership to the federal agencies and members of Congress regarding professional and reimbursement issues - reaching out to fellow professional associations, industry and other association partners to accomplish common goals.
Position statements, comments, and letters are usually generated by our Professional Relations and Economic Affairs Committees, though our Clinical Practice and Training & Education Committees do advocate in their areas. We invite you to explore AMP's Position Statements and Letters. For more information, please contact Mary Williams.
View all AMP Position Statements and Letters
AMP Comments to AHRQ on Genetic Testing
April 2013
AMP Reaffirms Comments to House on Health Information Technology Reform Act
April 2013
AMP Comments to FDA on Drug Labeling
March 2013
AMP Comments to FDA on Alternative Approval Pathways
March 2013
AMP Comments to USTPO on Genetic Diagnostic Testing
January 2013